Amid staggering numbers of reported Coronavirus (COVID-19) cases, the global population is faced with unprecedented challenges relating to the way we work, live, and function within society. COVID-19 has fundamentally changed the world as we know it and the stark reality is that there is no vaccine for the virus.
While the COVID-19 outlook remains grim, the public health crisis comes with one very significant silver lining. Around the world, companies across sectors – industrial, aerospace, automotive, medical, retail – are banding together to produce medical supplies to fight the pandemic.
For companies in the pharmaceutical space, the imperative is to rapidly accelerate production of COVID-19 testing supplies globally. Roche Diagnostics has emerged as a COVID-19 hero in this regard, developing the first commercially available test kit for the novel Coronavirus and enabling labs to expand and expedite testing to meet urgent medical needs.
Under the FDA’s Emergency Use Authorization authority, Roche’s new testing allows labs to process a high volume of patient samples and provide results to patients in just three and a half hours – roughly 10 times faster than existing tests. Roche began shipment of the cobas® SARS-CoV-2 Test for COVID-19 in March, with 400,000 tests going to testing sites across the U.S. Since that time, Roche has been shipping 400,000 tests per week across the nation – with plans to have millions of tests available per month around the globe.
Understanding the importance of Roche’s work, PTC has quickly mobilized with a cross-functional rapid response team across cloud services, R&D, product management, IoT Center of Excellence, software update management, tech support, and success management assisting Roche in remote monitoring, troubleshooting challenges, and swiftly resolving any issues that may arise.
Many thanks to Roche for their tireless efforts in fighting the COVID-19 pandemic. Our gratitude is endless.
Have a COVID-19 Hero you would like to nominate? Please reach out to Alexa Rice with details.